Stock Analysis of Acurx Pharmaceuticals LLC (ACXP) - Birds Eye View

1W   2W   1M   3M   1Y   2Y   5Y   
Overview
Code ACXP
Close 2.25
Change 0.090 / 4.17 %
Volume 38037.00
Vol Change -14980.00 / 28.26 %
IndustryBiotechnology
SectorHealthcare
AIO Strength Index
Technical StrengthMild Bullish
Growth Index Very Low Growth Stock
Value Index Poor Value Stock
Profitability Index Poor Profitability Stock
Stability Index Excellent Stability


Fundamental View of Acurx Pharmaceuticals LLC
PE (TTM)

-0.671

Very Poor
Price / Book

1.71

Good
Price / Sales

0

Very Poor
Piotroski F Score

1.0

Very Poor
Market Cap

35601.97 K

Enterprise Value

28127.79 K

ROA (TTM)

-166.33

Very Poor
ROE (TTM)

-254.90

Very Poor
Net Margin (TTM)

0

Poor
Revenue

%

0
Net Profit

5.21 %

-12723.69 K
Debt to Equity

0

Excellent
Altman Z Score

-7.36

Very Poor
Quick Ratio

0

Poor
Cash Ratio

2.46

Good


Highs/Lows of Acurx Pharmaceuticals LLC
PeriodOld priceStock ReturnS&P 500 ReturnsHighLowHigh DateLow Date
One Week2.03 10.84 % 1.54 % 2.362.0215-May-2414-May-24
Two Week2.17 3.69 % 3.42 % 2.361.8515-May-2409-May-24
One Month1.8 25.00 % 5.60 % 2.361.815-May-2418-Apr-24
Three Month3.225 30.23 % 5.95 % 3.351.5227-Feb-2416-Apr-24
Six Months3.7 39.19 % 17.48 % 5.281.5212-Jan-2416-Apr-24
One year3.14 28.34 % 27.52 % 8.821.1712-Oct-2302-Oct-23
Two year2.8 19.64 % 29.70 % 8.821.1712-Oct-2302-Oct-23


Technical View of Acurx Pharmaceuticals LLC
RSI

56.99

Neutral
MACD

0.0087

Strong Bullish
ADX

17.08

Bullish
Super Trend

1.77

Bullish
Williams %R

-21.57

Neutral
CCI

103.65

Mild Bearish


EMA 5

2.17

Bullish
EMA 15

2.11

Strong Bullish
EMA 50

2.26

Mild Bearish
EMA 100

2.57

Mild Bearish
SMA 100

2.85

Mild Bearish
SMA 200

2.90

Mild Bearish
SMA 5 / 20

2.17 / 2.09

Strong Bullish
SMA 15 / 50

2.11 / 2.15

Mild Bearish
SMA 50 / 200

2.15 / 2.90

Bearish




Charts of Acurx Pharmaceuticals LLC


Returns of Acurx Pharmaceuticals LLC with Peers
Period / StockACXPSTSAOWLTBCLI
1 Week10.84%4.76%-5.28%14.06%
1 Mth25.00%2.80%15.84%-3.83%
3 Mth-30.23%16.17%-11.43%39.18%
6mth-39.19%31.28%-32.13%188.94%
1 Year-28.34%-65.30%11.12%-81.16%
2 Year-19.64%-78.72%-92.63%-82.37%
5 Years----86.63%
charts-
View All Together in Chart      Inline           Tile

Compare Fundamentals of Acurx Pharmaceuticals LLC with Peers
Ratio / StockACXPSTSAOWLTBCLI
PE-0.671-0.368-374445.76-1.70
P/B1.710.567-425851.20-4.76
ROA-166.33-138.42-59.61-231.00
ROE-254.90-154.0600
Debt To Equity00.0029-0.512-0.089
Revenue0
% 		0
% 		800000
1056.07 % 		0
%
Net Income-12723.69 K
5.21 % 		-70055.00 K
36.90 % 		-32900.00 K
45030.32 % 		-16632.00 K
31.49 %


Technicals of Acurx Pharmaceuticals LLC with Peers
Technical / StockACXPSTSAOWLTBCLI-
ADX17.0832.8814.7424.39
CMF-0.03360.287-0.246-0.138
MFI56.4349.8339.7453.04
RSI56.9960.8245.3053.54
MACD Abv SignalTrueFalseFalseTrue
Price Above 50 MATrueTrueFalseTrue-
Price Above 200 MAFalseFalseFalseFalse-


About : Acurx Pharmaceuticals LLC

Address : 259 Liberty Avenue, Staten Island, NY, United States, 10305
Tel : 917 533 1469
URL : https://www.acurxpharma.com
Code : ACXP, ISIN : US00510M1045, Exchange : NASDAQ, Country : USA
Fiscal Year End : December
IPO date : 25_Jun_2021
Employee Count : 4

Acurx Pharmaceuticals, Inc., a clinical stage biopharmaceutical company, develops antibiotics to treat bacterial infections. The company's lead antibiotic candidate is ibezapolstat, a novel mechanism of action that targets the polymerase IIIC enzyme that is in Phase 2b clinical trial to treat patients with clostridium difficile infections. It also develops ACX-375C, a potential oral and parenteral treatment targeting gram-positive bacteria, including methicillin-resistant staphylococcus aureus, vancomycin-resistant enterococcus, and penicillin-resistant streptococcus pneumonia. Acurx Pharmaceuticals, Inc. was incorporated in 2017 and is headquartered in Staten Island, New York.


Note : All Data Generated at the End of Trading Hours (EOD Data)